Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
12 2020
Historique:
received: 15 05 2020
revised: 22 07 2020
accepted: 06 08 2020
pubmed: 3 10 2020
medline: 15 12 2020
entrez: 2 10 2020
Statut: ppublish

Résumé

To examine the association between blood-brain barrier (BBB) integrity, brain volume and cognitive dysfunction in adult patients with systemic lupus erythematosus (SLE). A total of 65 ambulatory patients with SLE and 9 healthy controls underwent dynamic contrast-enhanced MRI scanning, for quantitative assessment of BBB permeability. Volumetric data were extracted using the VolBrain pipeline. Global cognitive function was evaluated using a screening battery consisting of tasks falling into five broad cognitive domains, and was compared between patients with normal versus extensive BBB leakage. Patients with SLE had significantly higher levels of BBB leakage compared with controls (p=0.04). Extensive BBB leakage (affecting over >9% of brain volume) was identified only in patients with SLE (16/65; 24.6%), who also had smaller right and left cerebral grey matter volumes compared with controls (p=0.04). Extensive BBB leakage was associated with lower global cognitive scores (p=0.02), and with the presence of impairment on one or more cognitive tasks (p=0.01). Our findings provide evidence for a link between extensive BBB leakage and changes in both brain structure and cognitive function in patients with SLE. Future studies should investigate the mechanisms underlying BBB-mediated cognitive impairment, validate the diagnostic utility of BBB imaging, and determine the potential of targeting the BBB as a therapeutic strategy in patients with SLE.

Identifiants

pubmed: 33004325
pii: annrheumdis-2020-218004
doi: 10.1136/annrheumdis-2020-218004
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1580-1587

Subventions

Organisme : CIHR
ID : MOP-88526
Pays : Canada
Organisme : CIHR
ID : PJT148896
Pays : Canada

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Lyna Kamintsky (L)

Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.

Steven D Beyea (SD)

Biomedical Translational Imaging Centre (BIOTIC), Queen Elizabeth ll Health Sciences Centre, Halifax, Nova Scotia, Canada.
Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.

John D Fisk (JD)

Psychiatry, Psychology & Neuroscience and Medicine, Dalhousie University and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

Javeria A Hashmi (JA)

Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

Antonina Omisade (A)

Acquired Brain Injury (Epilepsy Program), Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

Cynthia Calkin (C)

Psychiatry and Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.
Mood Disorders Clinic, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

Tim Bardouille (T)

Physics, Dalhousie University, Halifax, Nova Scotia, Canada.

Chris Bowen (C)

Biomedical Translational Imaging Centre (BIOTIC), Queen Elizabeth ll Health Sciences Centre, Halifax, Nova Scotia, Canada.
Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.

Maher Quraan (M)

Biomedical Translational Imaging Centre (BIOTIC), Queen Elizabeth ll Health Sciences Centre, Halifax, Nova Scotia, Canada.
Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.

Arnold Mitnitski (A)

Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

Kara Matheson (K)

Research Methods Unit, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

Alon Friedman (A)

Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.
Cognitive and Brain Sciences, Physiology and Cell Biology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

John G Hanly (JG)

Medicine and Pathology, Queen Elizabeth ll Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada john.hanly@nshealth.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH